Literature DB >> 3499484

Single photon emission tomography using 99mTc-HM-PAO in the investigation of dementia.

D Neary1, J S Snowden, R A Shields, A W Burjan, B Northen, N MacDermott, M C Prescott, H J Testa.   

Abstract

Single photon emission tomographic imaging of the brain using 99mTc HM-PAO was carried out in patients with a clinical diagnosis of Alzheimer's disease, non-Alzheimer frontal-lobe dementia, and progressive supranuclear palsy. Independent assessment of reductions in uptake revealed posterior hemisphere abnormalities in the majority of the Alzheimer group, and selective anterior hemisphere abnormalities in both other groups. The findings were consistent with observed patterns of mental impairment. The imaging technique has potential value in the differential diagnosis of primary cerebral atrophy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499484      PMCID: PMC1032339          DOI: 10.1136/jnnp.50.9.1101

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  33 in total

1.  Alzheimer's disease: a correlative study.

Authors:  D Neary; J S Snowden; D M Mann; D M Bowen; N R Sims; B Northen; P O Yates; A N Davison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-03       Impact factor: 10.154

2.  The role of the psychiatrist.

Authors:  T F Rodger
Journal:  Br J Psychiatry       Date:  1966-01       Impact factor: 9.319

3.  Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

Authors:  E R Maher; E M Smith; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

4.  Neuropsychological syndromes in presenile dementia due to cerebral atrophy.

Authors:  D Neary; J S Snowden; D M Bowen; N R Sims; D M Mann; J S Benton; B Northen; P O Yates; A N Davison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-02       Impact factor: 10.154

5.  Dementia of the Alzheimer type. An inventory of diagnostic clinical features.

Authors:  J L Cummings; D F Benson
Journal:  J Am Geriatr Soc       Date:  1986-01       Impact factor: 5.562

6.  A 99Tcm-labelled radiotracer for the investigation of cerebral vascular disease.

Authors:  P J Ell; J M Hocknell; P H Jarritt; I Cullum; D Lui; D Campos-Costa; D P Nowotnik; R D Pickett; L R Canning; R D Neirinckx
Journal:  Nucl Med Commun       Date:  1985-08       Impact factor: 1.690

7.  Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy.

Authors:  R D'Antona; J C Baron; Y Samson; M Serdaru; F Viader; Y Agid; J Cambier
Journal:  Brain       Date:  1985-09       Impact factor: 13.501

8.  Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging.

Authors:  D P Nowotnik; L R Canning; S A Cumming; R C Harrison; B Higley; G Nechvatal; R D Pickett; I M Piper; V J Bayne; A M Forster
Journal:  Nucl Med Commun       Date:  1985-09       Impact factor: 1.690

9.  Towards a behavioral typology of Alzheimer's patients.

Authors:  A Martin; P Brouwers; F Lalonde; C Cox; P Teleska; P Fedio; N L Foster; T N Chase
Journal:  J Clin Exp Neuropsychol       Date:  1986-10       Impact factor: 2.475

10.  Positron emission tomography in Alzheimer's disease.

Authors:  R Duara; C Grady; J Haxby; M Sundaram; N R Cutler; L Heston; A Moore; N Schlageter; S Larson; S I Rapoport
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

View more
  42 in total

1.  Past glory and future promise: maximizing and improving understanding of atrophy patterns in the diagnosis of degenerative dementias.

Authors:  Bruce L Miller
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

2.  Semi-automatic quantification of regional cerebral perfusion in primary degenerative dementia using 99m technetium-hexamethylpropylene amine oxime and single photon emission tomography.

Authors:  P Goulding; A Burjan; R Smith; R Lawson; J Snowden; B Northen; D Neary; H Testa
Journal:  Eur J Nucl Med       Date:  1990

3.  A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia.

Authors:  M O Habert; U Spampinato; J L Mas; M L Piketty; M C Bourdel; J de Recondo; P Rondot; S Askienazy
Journal:  Eur J Nucl Med       Date:  1991

4.  Association between medial temporal lobe atrophy on CT and parietotemporal uptake decrease on SPECT in Alzheimer's disease.

Authors:  I Lavenu; F Pasquier; F Lebert; B Jacob; H Petit
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

5.  Qualitative neuropsychological performance characteristics in frontotemporal dementia and Alzheimer's disease.

Authors:  J C Thompson; C L Stopford; J S Snowden; D Neary
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

Review 6.  The new neuropathology of degenerative frontotemporal dementias.

Authors:  M Jackson; J Lowe
Journal:  Acta Neuropathol       Date:  1996       Impact factor: 17.088

7.  Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients.

Authors:  Kathy Dujardin; Luc Defebvre; Alain Duhamel; Pascal Lecouffe; Pascal Rogelet; Marc Steinling; Alain Destée
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

8.  Artificial neural networks that use single-photon emission tomography to identify patients with probable Alzheimer's disease.

Authors:  M R Dawson; A Dobbs; H R Hooper; A J McEwan; J Triscott; J Cooney
Journal:  Eur J Nucl Med       Date:  1994-12

9.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

10.  Quantification of functional deficit in Alzheimer's disease using a computer-assisted mapping program for 99mTc-HMPAO SPECT.

Authors:  H Karbe; A Kertesz; J Davis; B J Kemp; F S Prato; R L Nicholson
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.